Ultragenyx Pharmaceutical | RARE - Gross Profit On Sales


Ultragenyx Pharmaceutical reported $178M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Immunic 0 0 Mar/2025
Insmed USD 217.69M 106.25M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Kyowa Hakko Kirin JPY 109.5B 18.9B Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Moderna USD 226M 583M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025
Xoma 992K 846K Jun/2024